Genor Announces Collaboration with Hutchison MediPharma to Evaluate Combination of Genolimzumab and Fruquintinib in Solid Tumors
– Collaboration to evaluate Genor’s anti-PD-1 monoclonal antibody genolimzumab in combination with Hutchison MediPharma’s VEGFR inhibitor fruquintinib –
– Expected to initiate clinical development of combination therapy in China in late 2018 –
Shanghai: October 29th, 2018: Genor Biopharma Co. Ltd. (“Genor”) today announces that it has entered into a collaboration agreement with Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), through its Innovation Platform subsidiary Hutchison MediPharma Limited, to evaluate the safety, tolerability and efficacy of Genor’s genolimzumab in combination with Hutchison MediPharma’s fruquintinib in patients with certain advanced solid tumors in China.
Genolimzumab (GB226) is an investigational, humanized, IgG4 monoclonal antibody targeting the programmed cell death-1 receptor (“PD-1”) on immune cells, designed to restore the natural ability of the immune system to recognize and kill cancer cells by selectively blocking the dual ligand (PD-L1 and PD-L2) binding to the PD-1 protein. It is currently in Phase II clinical trials for multiple tumor indications in China. Outside China, genolimzumab is being developed by CBT Pharmaceuticals, Inc. as CBT-501.
Fruquintinib (HMPL-013) is a highly selective and potent oral inhibitor of vascular endothelial growth factor (“VEGF”) receptors 1/2/3 that was designed to be a global best-in-class VEGFR inhibitor for many types of solid tumors. Fruquintinib's unique kinase selectivity has been shown to reduce off-target toxicity thereby allowing for better target coverage, as well as possible use in combination with other agents such as chemotherapies, targeted therapies and immunotherapies. Fruquintinib capsules were granted approval for drug registration by the National Medical Products Administration of China (“NMPA”, formerly the China Food and Drug Administration) for the treatment of metastatic colorectal cancer (“CRC”).
“Immunotherapies and targeted therapies have both delivered improved outcomes for patients as single agents,” said Dr. Joe Zhou, Chief Executive Officer of Genor. “Combining genolimzumab, our PD-1 inhibitor having higher affinity, comparable safety and preliminary efficacy profile to the marketed anti-PD-1 antibody, with fruquintinib, could represent an ideal combination to extend the duration of these benefits and expand them to more patients.”
Under the terms of the agreement, Genor and Hutchison MediPharma will collaborate initially to evaluate the combination of the two drugs across a number of defined solid tumor types. The first Phase Ib studies are expected to begin enrolling patients in China in late 2018 to establish the safety and recommended dose regimen of genolimzumab in combination with fruquintinib in the selected tumor types. Data from these studies may lead to subsequent Phase III registration studies to establish the safety and efficacy of the combination in China.
Genor Biopharma is a leading biopharmaceutical company in China, developing and commercializing innovative therapeutic antibodies and recombinant fusion proteins. With ten products in different clinical stages, Genor has a strong pipeline in oncology and other major diseases, and has built a fully-integrated and well-proven technology platform in antibody drug research, development and manufacturing to serve China and international patients.
Genor is majority owned by HH CT Holdings Limited (affiliated funds to HillHouse Capital), and its other important shareholders include Zhejiang Conba Pharmaceutical Co., Ltd (Shanghai Stock Exchange: 600572) and Walvax Biotechnology Co., Ltd. (Shenzhen Stock Exchange: 300142). For additional information, please visit www.genorbio.com.
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited(SEHK: 1). For more information, please visit: www.chi-med.com.